Study | Treatments | KRAS | N (%) | RR, N (%) | TTP (months) | OS (months) | Remarks |
---|---|---|---|---|---|---|---|
Bokemeyer, 2008 | FOLFOX + CTX | WT | 61 | 37 (60.7%) | 7.7 | NA | KRAS MT has worse RR and TTP. Cetuximab may have detrimental effects in KRAS MT. |
 |  | MT | 52 (46.0%) | 17 (32.7%) | 5.5 | NA |  |
 | FOLFOX | WT | 73 | 27 (37.0%) | 7.2 | NA |  |
 |  | MT | 47 (39.2%) | 23 (48.9%) | 8.6 | NA |  |
Cervantes, 2008 | CTX | WT | 29 | 8 (27.6%) | NA | NA | Patients were treated with CTX first, then in combination with chemo. KRAS MT has worse RR and TTP. |
 |  | MT | 19 (39.6%) | 0 | NA | NA |  |
 | CTX + FOLFIRI | WT | 29 | 16 (55.2%) | 9.4 | NA |  |
 |  | MT | 19 (39.6%) | 6 (31.6%) | 5.6 | NA |  |
Punt, 2008 | CapOxBev+CTX | WT | 153 | NA | 10.5 | 22.2 | KRAS MT has worse TTP, and OS. Cetuximab may have detrimental effects in KRAS MT. |
 |  | MT | 93 (37.8%) | NA | 8.6 | 19.1 |  |
 | CapOxBev | WT | 152 | NA | 10.7 | 23.0 |  |
 |  | MT | 103 (40.4%) | NA | 12.5 | 24.9 |  |
Van Custem, 2008 | FOLFIRI + CTX | WT | 172 | 102 (59.3%) | 9.9 | NA | KRAS MT has worse RR and TTP. Cetuximab may have detrimental effects in KRAS MT. |
 |  | MT | 105 (37.9%) | 38 (36.2%) | 7.6 | NA |  |
 | FOLFIRI | WT | 176 | 76 (43.2%) | 8.7 | NA |  |
 |  | MT | 87 (33.1%) | 35 (40.2%) | 8.1 | NA |  |